Skip to content
Parnaparin sodium
Parnaparin sodium is an oligosaccharide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Retinal vein occlusionD012170EFO_1001157H34.81——1——1
InfertilityD007246EFO_0000545——1——1
ThrombophlebitisD013924HP_0004418——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePARNAPARIN SODIUM
INNparnaparin sodium
Description
Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins. In the prevention and therapy of thromboembolic pathologies, the advent of this class of drugs represented a medical development, since they retain the same effectiveness of unfractionated heparin but with simpler dosing regimens and decreased side effects. In addition to being effective in treating proven deep vein thrombosis and thrombosis-associated phlebopathies, Parnaparin has demonstrated its thromboprophylactic efficacy in both high- and moderate-risk surgical patients.
Classification
Oligosaccharide
Drug classheparin derivatives and low molecular weight (or depolymerized) heparins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID91449-79-5
RxCUI—
ChEMBL IDCHEMBL2108080
ChEBI ID—
PubChem CID—
DrugBankDB09260
UNII IDU6K360XMIU (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 21 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2 adverse events reported
View more details